FSC Urges Life Insurers to Clarify Medical Necessity to Reduce Disputes

Recently, "medical necessity" has ranked first among life insurance claim dispute categories for several consecutive years. According to statistics from the Financial Supervisory Commission (FSC), complaints related to this issue are not only high in volume, but also predominantly concentrated on divergences in judgment regarding whether medical expenses qualify as "necessary," resulting in a gap between claim outcomes and policyholders' expectations. This phenomenon reflects ongoing issues of information asymmetry and cognitive gaps between product explanations and practical operations in medical insurance.

The distinction between "necessary medical care" and "unnecessary medical care" is primarily based on professional medical opinions and clinical guidelines, determining whether a specific treatment constitutes a basic medical need for sustaining life or preventing the deterioration of a condition. Conversely, cosmetic surgery, elective procedures, or unproven emerging therapies are often classified as non-essential medical care. When purchasing insurance, policyholders often find it difficult to foresee whether future medical items will meet the "necessity" standard. If insurance companies rely solely on the results of medical reviews when processing claims, rejections can easily occur, further exacerbating complaints and disputes.

In response to these circumstances, the FSC officially confirmed today that it has required all insurance companies to strengthen information disclosure and warning reminders during the solicitation and renewal processes of medical insurance. Specific measures include: clearly labeling in official company websites, underwriting prospectuses, renewal notices, and other documents that claim payouts will refer to professional medical opinions to evaluate medical necessity; meanwhile, insurance providers must explain to policyholders during sales presentations or customer service inquiries under what circumstances treatments may be deemed non-essential and thus excluded from coverage. This move aims to enhance risk awareness prior to purchase and reduce claim disputes arising from information asymmetry in the future.

For insurance companies, strengthening information disclosure will directly impact their underwriting and claims processing workflows. First, providers must review their policy terms and marketing materials to ensure that the wording complies with the FSC's disclosure standards, avoiding misleading interpretations caused by ambiguous language. Second, claims departments must strengthen cooperation with medical institutions to ensure that the acquired medical opinions possess sufficient objectivity and professionalism, thereby reducing the scope for disputes in claim reviews. Although this may increase operational costs, in the long run, it will help enhance consumer trust and mitigate brand damage and litigation risks resulting from claim disputes.

From the consumer perspective, there is an expectation for policy terms to be more transparent and easier to understand. In the past, many policyholders reported that the criteria for determining the "necessity" of medical insurance were often only disclosed at the time of a claim, lacking clear prior explanation and leaving insurance purchase decisions without complete information. If the FSC's directive can be effectively implemented in practice, it will help policyholders grasp the scope of coverage prior to purchasing, reduce the financial and psychological stress caused by claim rejections, and simultaneously foster a healthier competitive environment in product design and service quality within the insurance market.

In summary, the FSC's requirement for the insurance industry to strengthen medical insurance information disclosure is not only an immediate response to recent claim disputes, but also an important step in upgrading the overall financial consumer protection mechanism. If continuous supervision of industry compliance can be maintained in the future, coupled with consumer education, it is expected to establish a more transparent and reasonable claims ecosystem in the medical insurance sector, reduce unnecessary conflicts and disputes, and promote the sustainable development of the insurance market.